Table 5.

Associations between sputum inflammatory phenotypes and clinical outcomes.

Asthma population	Patient number (N), [REF]	Sputum cells	Clinical marker
Mild asthma Steroid naive	N = 213 [Boulay et al. (82)]	Eos > 2%	↓ control
Mild to moderate steroid naïve nonsmoking	N = 51, [Godon et al. (83); 20: 1364–1369]	Eos > 2%	→ Symptoms → QoL → FEV1 → BHR
Mild to moderate Treated ICS/OCS	N = 995 [McGrath et al. (71)]	Eos ≥3 %	↑control ↓age ↓BMI ↓BHR
Mild to severe Treated and untreated with ICS nonsmoking (SARP cohort)	N = 242 [Hastie et al. (67)]	Eos ≥2%	↑use of β-agonist ↑daily wheeze
		Mixed eos / Neu	↓ FEV1 ↑ Symptoms ↑Healthcare resources
Mild to severe Treated and untreated with ICS Included smokers	N = 508 [Schleich et al. (30)]	Eos ≥2%	↑ Atopy ↑ AHR ↓ control (ACT)
		Mixed eos /Neu	↑AHR ↓FEV1
Mild to severe Treated ICS/OCS Smokers included (U-BIOPRED cohort)	N = 509 [Shaw et al. (84)]	Eos > 1,9%	↓FEV1 ↑BMI ↑Exhacerbations ↑Intensive care

↓lower; ↑higher; → no correlation; QoL = quality of life; BHR, bronchial hyperresponsiveness.